Subject(s)
Infusion Pumps, Implantable/adverse effects , Insulin Infusion Systems/adverse effects , Mycobacterium Infections, Nontuberculous/etiology , Mycobacterium fortuitum , Adult , Diabetes Mellitus, Type 1/drug therapy , Female , Humans , Hypoglycemic Agents/administration & dosage , Insulins/administration & dosageABSTRACT
La talidomida es el fármaco de elección en el tratamiento del eritema nodoso leproso severo/recurrente. Su uso ha sido relacionado con trombosis venosas profundas (TVP) en pacientes con enfermedades hematológicas (especialmente cuando se le asocia con corticoides y quimioterapia). Presentamos un caso de TVP en un hombre de 43 años, con lepra lepromatosa en tratamiento con talidomida y prednisona por una leprorreación tipo 2 (eritema nodoso leproso), con anticuerpos antifosfolípidos positivos transitorios. Resaltamos la importancia de tener en cuenta esta posible complicación, potencialmente fatal, en pacientes tratados con talidomida por enfermedades dermatológicas (AU)
Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum. Its use has been associated with deep vein thrombosis in patients with blood disorders, however, particularly when used in combination with corticosteroids or chemotherapy. We describe a case of deep vein thrombosis in a 43-year-old man with lepromatous leprosy who was being treated with thalidomide and prednisone for a type 2 leprosy reaction (erythema nodosum leprosum); the patient also had transiently positive antiphospholipid antibody results. We stress the importance of considering deep vein thrombosis, a potentially fatal complication, in dermatology patients treated with thalidomide (AU)
Subject(s)
Humans , Venous Thrombosis/chemically induced , Leprosy, Lepromatous/complications , Thalidomide/adverse effects , Thalidomide/therapeutic use , Leprosy, Lepromatous/drug therapy , Drug InteractionsABSTRACT
Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum. Its use has been associated with deep vein thrombosis in patients with blood disorders, however, particularly when used in combination with corticosteroids or chemotherapy. We describe a case of deep vein thrombosis in a 43-year-old man with lepromatous leprosy who was being treated with thalidomide and prednisone for a type 2 leprosy reaction (erythema nodosum leprosum); the patient also had transiently positive antiphospholipid antibody results. We stress the importance of considering deep vein thrombosis, a potentially fatal complication, in dermatology patients treated with thalidomide.
Subject(s)
Leprostatic Agents/adverse effects , Leprosy, Lepromatous/drug therapy , Thalidomide/adverse effects , Venous Thrombosis/chemically induced , Adult , Humans , Leprostatic Agents/therapeutic use , Male , Thalidomide/therapeutic useABSTRACT
La sarcoidosis es una enfermedad crónica multisistémica de etiología desconocida. La histiocitosis eruptiva generalizada (HEG) es una forma rara de histiocitosis no Langerhans, de curso benigno y autorresolutivo. Presentamos el caso de una niña de 8 años de edad con sarcoidosis que fue inicialmente diagnosticada en forma errónea de HEG. Fue tratada con corticoides orales, metotrexato y adalimumab, con los que se logró un control insuficiente de la uveítis. La introducción de infliximab permitió un control del compromiso oftalmológico y reducir la dosis de corticoides. En algunos casos de sarcoidosis la falta de granulomas bien organizados en el inicio de la enfermedad, así como la presencia de células gigantes, puede sugerir diagnósticos alternativos como la histiocitosis no Langerhans. Aunque la experiencia del uso de antagonistas del factor de necrosis tumoral alfa en niños con sarcoidosis es limitada, puede ser útil en aquellos pacientes con enfermedad severa y refractaria(AU)
Sarcoidosis is a chronic multisystemic granulomatous disease of unknown origin. Generalised eruptive histiocytosis is a rare, benign, self-healing, non-Langerhans cell histiocytosis (non-LCH).We report the case of an 8-year-old girl with sarcoidosis who was misdiagnosed as non-LCH. She was treated with oral corticosteroids, methotrexate and adalimumab, but there was insufficient control of ocular disease. The introduction of infliximab achieved a control of the uveitis and enabled the corticosteroid dose to be tapered. In some cases of sarcoidosis the lack of well-organised granuloma formation at the beginning of the disease, and the presence of prominent giant cells may suggest alternative diagnoses, such as non-LCH. Although the experience of tumour necrosis factor-alpha antagonists use in children with sarcoidosis is limited, these drugs may be helpful for those patients experiencing a severe and refractory disease(AU)
Subject(s)
Humans , Female , Child , Sarcoidosis/diagnosis , Histiocytosis, Non-Langerhans-Cell/diagnosis , Diagnosis, Differential , Uveitis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitorsABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Hamartoma/complications , Hamartoma/diagnosis , Hamartoma/mortality , Hamartoma/prevention & control , Hamartoma/surgery , Hamartoma/therapyABSTRACT
Sarcoidosis is a chronic multisystemic granulomatous disease of unknown origin. Generalised eruptive histiocytosis is a rare, benign, self-healing, non-Langerhans' cell histiocytosis (non-LCH). We report the case of an 8-year-old girl with sarcoidosis who was misdiagnosed as non-LCH. She was treated with oral corticosteroids, methotrexate and adalimumab, but there was insufficient control of ocular disease. The introduction of infliximab achieved a control of the uveitis and enabled the corticosteroid dose to be tapered. In some cases of sarcoidosis the lack of well-organised granuloma formation at the beginning of the disease, and the presence of prominent giant cells may suggest alternative diagnoses, such as non-LCH. Although the experience of tumour necrosis factor-α antagonists use in children with sarcoidosis is limited, these drugs may be helpful for those patients experiencing a severe and refractory disease.
